Non-small cell lung cancer is a group of lung cancers that behave similarly, such as squamous cell carcinoma and adenocarcinoma. Non-small cell lung cancer (NSCLC) treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.
Global non-small cell lung cancer treatment market is estimated to be valued at US$ 24,910.7 million in 2022 and is expected to exhibit a CAGR of 9.4% during the forecast period (2022-2030).
Figure 1. Global Non-small Cell Lung Cancer Treatment Market Share (%), by End User, 2022
Increasing new drug approvals for the treatment of non-small cell lung cancer are expected to drive the market growth.
Increasing new drug approvals for the treatment of non-small cell lung cancer are expected to drive the market growth. For instance, in August 2019, Roche Holding, which is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics, received the U.S. Food and Drug Administration (FDA) approval for Rozlytrek (entrectinib), which is indicated for the treatment of adults with ROS1-positive, metastatic Non-small cell lung cancer.
Figure 2. Global Non-small Cell Lung Cancer Treatment Market Share (%), by Region, 2022
Increasing prevalence of non-small cell lung cancer is expected to drive market growth during the forecast period.
Increasing prevalence of non-small cell lung cancer is expected to drive market growth during the forecast period. For instance according to data published in May 2020, by the American Lung Association, which is a voluntary health organization whose mission is to save lives by improving lung health and preventing lung disease through education, advocacy and research, stated that in 2018, an estimated 234,030 cases of lung cancer were diagnosed in the U.S.
|Base Year:||2021||Market Size in 2022:||US$ 24,910.7 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||9.4%||2030 Value Projection:||US$ 50,962.7 Mn|
Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
|Restraints & Challenges:||
Global Non-small Cell Lung Cancer Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.
The market for non-small cell lung cancer diagnostics was affected by restrictions on a number of screening, diagnostic, and surgical procedures at hospitals and cancer treatment facilities. However, lung cancer cases continued even throughout the pandemic, which is expected to increase demand for non-small cell lung cancer diagnostics.
Global Non-small Cell Lung Cancer Treatment Market: Key Developments
On August 23, 2021, Pfizer, which is a U.S.-based multinational pharmaceutical and biotechnology corporation acquired Trillium Therapeutics Inc., which is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. This acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
On March 6, 2022, Bristol Myers Squibb, which is an U.S.-based multinational pharmaceutical company, acquired Turning Point Therapeutics, which is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The acquisition of Turning Point Therapeutics broadened the company’s oncology franchise by adding a best-in-class, late-stage precision oncology asset.
Global Non-small Cell Lung Cancer Treatment Market: Restraint
The high cost of drugs is a major barrier for patients to adopt these drugs easily. High cost of drugs used in non-small cell lung cancer treatment is a major factor that is expected to restrain growth of market.
Major players operating in the global non-small cell lung cancer treatment market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
Lung cancer symptoms are not noticeable in its early stage as these symptoms are considered for other type of illness such as pneumonia or collapsed lung. Some symptoms of lung cancer include chest pain, harsh/raspy sound while breathing, wheezing, weight loss, continuous cough, hoarseness or voice changes, shortness of breath, lung problems such as bronchitis or pneumonia, and others. Moreover, if it spreads through the bloodstream or the lymphatics into other parts of the body then it exhibits symptoms such as bone pain, weakness in arm or leg, yellow skin, yellow eyes, headache, and seizures.
Some diagnostic tests are performed by doctors to detect lung cancer, which include diagnostic imaging tests such as X-ray, magnetic resonance imaging (MRI), ultrasound, computed tomography scan (CT scan), and also by diagnosing mucous, which the patient can cough up to check the presence of cancer cells, which is called as sputum cytology. By taking the cells of lungs from abnormal growth area of the lung or from the fluid of lungs through the procedure called as fine needle aspiration biopsy, bronchoscopy, and mediastinoscopy, lung cancer can be diagnosed.
Increasing consumption of tobacco and active engagement in passive smoking are two major factors responsible for non-small cell lung cancer, which are expected to drive market growth over the forecast period. For instance, according to data published in March 2022, on The Centers for Disease Control and Prevention (CDC), stated that nearly 40 million U.S. adults smoke cigarettes, and an estimated 2.55 million middle and high school students use at least one tobacco product, including e-cigarettes every year.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients